У нас вы можете посмотреть бесплатно Virtual Crossmatches in Real Life-New CMS Guidelines или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
This AST Communities of Practice webinar is on: "Virtual Crossmatches in Real Life-New CMS Guidelines" Recorded live on Monday, February 10, 2025 This webinar was hosted by the AST Transplant Diagnostics Community of Practice (TxDx COP) and support by the AST Community of Transplant Scientists (COTS). Presenters: Luis G. Hidalgo, Ph.D., D(ABHI) • Director - HLA Laboratory, Associate Professor - Dept. of Surgery, University of Wisconsin – Madison William C. Goggins, MD, FACS, F(ACHI) • Professor of Surgery, Surgical Director Renal Transplantation, Co-Director, Transplant Immunology Laboratory, Indiana University School of Medicine Moderators: Qingyong Xu, Ph.D., D(ABHI), F(ACHI) • Co-Director, Histocompatibility Laboratory, University of Pittsburgh Medical Center (UPMC), Assistant Professor, Pathology and Thomas E. Starzl Transplantation Institute, University of Pittsburgh Yousuf Kyeso, MD, FASN • Assistant Professor of Medicine, Transplant Nephrology, University of Chicago Medicine Background: The Virtual crossmatch (VXM) assesses immunologic compatibility between recipient and potential donor through an in silico analysis of a recipient’s HLA antibody profile cross referenced against a donor’s HLA type. The goal of VXM is pre-transplant risk stratification—though there is no consensus on whether such risk assessment involves predicting the PXM result or the posttransplant outcome. Although the concept of VXM is not new, the wide application of single antigen bead assays for accurate and sensitive detection of recipient HLA antibodies and molecular methods for typing donor HLA at a higher resolution makes the routine use of VXM a reality. Implementation of VXMs allowed for expedited allocation of donor organs leading to reduced cold ischemia time without an increase in hyperacute rejection episodes. New regulations from CMS now consider VXM as a suitable alternative to cell-based crossmatches. In this webinar, we will be discussing new CMS guidelines related to VXM, and its impact on the transplant programs, HLA laboratories, and offer accepting providers standpoint. --- Learn more about AST's Communities of Practice at https://www.myast.org/cops